Board of Directors
|Nominating & Corporate
Chair of Board
President & Chief Operating Officer,
Jazz Pharmaceuticals, plc.
|Timothy B. Anderson
Former Senior Vice President, Baxter International Inc.
|Eric H. Bjerkholt||(bio)||—||—||Chair|
|William ‘Obi’ Greenman
President & Chief Executive Officer
|Timothy L. Moore||(bio)||—||Member||—|
Former Chairman, Zosano Pharma
Former President & Chief Executive Officer, Affymetrix, inc
Dan Swisher – Mr. Swisher has served as a member of our Board since June 2011 and has served as Chair of the Board since October 2013. He was appointed President and Chief Operating Officer of Jazz Pharmaceuticals as of January 2018. From December 2003 to December 2017, he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001, Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. In addition to serving on Cerus’ Board, he currently serves as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions.
Timothy B. Anderson – Mr. Anderson has served as a member of our Board since 2003. He was Senior Vice President of Strategy and Business Development of Baxter International, Inc., a pharmaceutical company, from 1999 until 2002, and held various management positions at Baxter International from 1992 to 1999, including President, Biotech Group from 1992 until 1997, Group Vice President from 1993 until 1997 and Chairman, Baxter Europe from 1997 until 1999. Mr. Anderson is currently a director of Lake Forest Hospital and a member of the Scientific Advisory Board of Baxter International.
Eric H. Bjerkholt – Mr. Bjerkholt has served as a member of our Board and member of the Audit Committee since October 2018. He is currently the Chief Financial Officer of Aimmune Therapeutics, Inc., a biotechnology company developing treatments for food allergies. From 2004 to 2017, he served as Chief Financial Officer at Sunesis Pharmaceuticals, Inc., expanding his role over those 13 years to overseeing business development and multiple aspects of governance and corporate relations. Prior to Sunesis, Mr. Bjerkholt was Chief Financial Officer at IntraBiotics Pharmaceuticals, Inc., and LifeSpring Nutrition, Inc. He began his healthcare career at J.P. Morgan & Co. as an investment banker in New York. He has served on the boards of directors of several publicly traded companies and is currently a member of the board of directors and chair of the audit committee of Corium International, Inc. He holds a Cand. Oecon degree in Economics from the University of Oslo and an M.B.A. from Harvard Business School.
William ‘Obi’ Greenman – Mr. Greenman was named our President and Chief Executive Officer in April 2011. He had been Cerus’ Chief Business Officer since April 2010. Previously, he was senior vice president, business development and marketing. From 2006 to 2008, he held the position of president, Cerus Europe, and prior to that, he served as vice president, business development. Prior to joining Cerus in 1995 as director of business development, he worked in various marketing and business development positions in Baxter’s Biotech Division from 1991 to 1995. Mr. Greenman currently is a member of the Board of Directors of Aduro Biotech. He received his B.A.S. in Economics and Biological Sciences from Stanford University.
Timothy L. Moore – Mr. Moore has served as a member of our Board and member of the Compensation Committee since September 2018. He is currently Executive Vice President, Technical Operations of Kite Pharma, a Gilead Company. Prior to Kite, he spent more than 12 years at Genentech, a Roche Company, most recently as Senior Vice President, Head of Global Technical Operations – Biologics and a member of the Genentech Executive Committee. While at Genentech, he oversaw global leadership for more than 7,500 professionals across 10 internal sites and managed more than 30 contract manufacturing organizations, including end to end quality supply performance of more than 20 biological products. Mr. Moore is currently a member of the board of directors FusionKite, a joint venture between Gilead Sciences, Inc. and Fusion Pharmaceuticals Inc. He holds a Bachelor of Science, Chemical Engineering from Tulsa University and a Masters of Science from Northwestern University.
Jami Nachtsheim – Ms. Nachtsheim has served on the Board of Intuitive Surgical since April 2017. Ms. Nachtsheim’s other board experiences include FEI Company from 2010 to 2016, Affymetrix from 2009 to 2016 and as chair from 2015 to 2016, and Southwall Technologies from 2003 to 2011. Earlier in her career, Ms. Nachtsheim served in a variety of senior leadership roles at Intel Corporation from 1980 until 2000, including corporate vice president of the sales and marketing group and director of worldwide marketing responsible for the Intel Inside® program.
Gail Schulze – Ms. Schulze has served as a member of our Board since October 2007. She is the former Chairman of Zosano Pharma, a private late-stage transdermal drug delivery company. Prior to joining Zosano, she was CEO of YM Biosciences US and president, YM Biosciences, Inc., a global biopharmaceutical organization. Prior to joining YM Biosciences in 2006, she was president, CEO and director of Eximias Pharmaceutical Corporation. From 2001 to 2004, Ms. Schulze was COO and deputy CEO of Aventis Behring LLC, an independent biologics subsidiary of Aventis, and from 1997 to 2001, was senior executive vice president and chief commercial officer. From 1996 to 1997 she was corporate vice president of Allegiance Healthcare Corporation and from 1979 to 1996 Ms. Schulze held multiple positions within Baxter Healthcare Corporation, most recently as president of the US Managed Care division and president of Renal Division Europe. Ms. Schulze has served on multiple private and public boards of companies focusing on medical technology and chronic therapy market development.
Frank Witney – Frank Witney, Ph.D., has served as a member of our Board since March 2014. Mr. Witney has served as President, Chief Executive Officer and a director of Affymetrix, Inc. from 2011 to 2016. Dr. Witney served as President and Chief Executive Officer of Dionex Corporation from April 2009 to May 2011. Between December 2008 and April 2009, Dr. Witney served as Affymetrix’ Executive Vice President and Chief Commercial Officer. Prior to that, Dr. Witney served as President and Chief Executive Officer of Panomics, Inc. from July 2002 to December 2008. Dr. Witney was a post-doctoral fellow at the National Institutes of Health and holds a Ph.D. in Molecular and Cellular Biology and an M.S. in Microbiology from Indiana University, and B.S. in Microbiology from the University of Illinois.